High) and AST (Class IV
To date, no studies have demonstrated superiority of SGLT2 inhibitors, GLP1-RAs, or glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists (GIP/GLP1- RAs) over metformin as first-line therapy in people newly diagnosed with type 2 diabetes
Chen, X., Zhao, P., Wang, W., Guo, L
We provide structured follow-up visits to review progress, monitor response, adjust treatment plans, and support long-term success through continued medical oversight
Lets make sure your care plan is complete, from food to fluids
[14, 15, 16, 17, 18, 19, 20] For detailed information on the serendipity discovery of GIP and its functional studies, please see nice review articles and other publications elsewhere, [21, 22, 23] including the In Memoriam composed by Timothy Kieffer (a formal PhD student of late professor John Brown) in 2017